Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Zhao

Showing results (911-920 of 1,180) with videos related to

Pageof 118
Sort By:
Prostate Cancer and Prostatic Diseases|May 25, 2016
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-upD E Spratt, W C Jackson, A Abugharib, et al.
Multiple Sclerosis and Related Disorders|December 6, 2021
Diffusely abnormal white matter in clinically isolated syndrome is associated with parenchymal loss and elevated neurofilament levelsI M Vavasour, P Becquart, J Gill, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
BJU International|March 25, 2016
Independent surgical validation of the new prostate cancer grade-grouping systemDaniel E Spratt, Adam I Cole, Ganesh S Palapattu, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2016
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysisB Benzon, S G Zhao, M C Haffner, et al.
Pageof 118

Showing results (911-920 of 1,180) with videos related to

Sort By:
Pageof 118
Prostate Cancer and Prostatic Diseases|May 25, 2016
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-upD E Spratt, W C Jackson, A Abugharib, et al.
Multiple Sclerosis and Related Disorders|December 6, 2021
Diffusely abnormal white matter in clinically isolated syndrome is associated with parenchymal loss and elevated neurofilament levelsI M Vavasour, P Becquart, J Gill, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.
BJU International|March 25, 2016
Independent surgical validation of the new prostate cancer grade-grouping systemDaniel E Spratt, Adam I Cole, Ganesh S Palapattu, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2016
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysisB Benzon, S G Zhao, M C Haffner, et al.
Pageof 118